These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1973734)

  • 1. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.
    Högberg T; de Paulis T; Johansson L; Kumar Y; Hall H; Ogren SO
    J Med Chem; 1990 Aug; 33(8):2305-9. PubMed ID: 1973734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
    Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
    J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
    Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds.
    Högberg T; Bengtsson S; de Paulis T; Johansson L; Ström P; Hall H; Ogren SO
    J Med Chem; 1990 Apr; 33(4):1155-63. PubMed ID: 1969484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.
    de Paulis T; Kumar Y; Johansson L; Rämsby S; Florvall L; Hall H; Angeby-Möller K; Ogren SO
    J Med Chem; 1985 Sep; 28(9):1263-9. PubMed ID: 4040977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidopaminergic effects of the stereoisomers of N-[(1-alkyl-2- pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides.
    Murakami S; Marubayashi N; Fukuda T; Takehara S; Tahara T
    J Med Chem; 1991 Jan; 34(1):261-7. PubMed ID: 1825115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
    Kung HF; Kasliwal R; Pan SG; Kung MP; Mach RH; Guo YZ
    J Med Chem; 1988 May; 31(5):1039-43. PubMed ID: 2966245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
    Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.
    de Paulis T; Kumar Y; Johansson L; Rämsby S; Hall H; Sällemark M; Angeby-Möller K; Ogren SO
    J Med Chem; 1986 Jan; 29(1):61-9. PubMed ID: 3941414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.
    Bishop JE; Mathis CA; Gerdes JM; Whitney JM; Eaton AM; Mailman RB
    J Med Chem; 1991 May; 34(5):1612-24. PubMed ID: 1827843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformationally restricted analogues of remoxipride as potential antipsychotic agents.
    Norman MH; Kelley JL; Hollingsworth EB
    J Med Chem; 1993 Oct; 36(22):3417-23. PubMed ID: 7901417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A; Gustafsson K; Andersson I
    Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
    Hall H; Sällemark M; Jerning E
    Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):61-70. PubMed ID: 2869639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors.
    Köhler C; Hall H; Gawell L
    Eur J Pharmacol; 1986 Jan; 120(2):217-26. PubMed ID: 3948920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
    van Wijngaarden I; Kruse CG; van Hes R; van der Heyden JA; Tulp MT
    J Med Chem; 1987 Nov; 30(11):2099-104. PubMed ID: 2889830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.
    Högberg T; Rämsby S; de Paulis T; Stensland B; Csöregh I; Wägner A
    Mol Pharmacol; 1986 Oct; 30(4):345-51. PubMed ID: 2945089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.
    de Paulis T
    Curr Pharm Des; 2003; 9(8):673-96. PubMed ID: 12570798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities.
    Florvall L; Ogren SO
    J Med Chem; 1982 Nov; 25(11):1280-6. PubMed ID: 6128419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.